

Global IgA Nephropathy Therapeutics Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G1A8F26503BEEN.html>

Date: July 2026

Pages: 201

Price: US\$ 3,660.00 (Single User License)

ID: G1A8F26503BEEN

Abstracts

The global IgA Nephropathy Therapeutics market size is predicted to grow from US\$ 1516 million in 2025 to US\$ 4474 million in 2032; it is expected to grow at a CAGR of 16.6% from 2026 to 2032.

IgA Nephropathy Therapeutics are a group of prescription medicines designed to delay or modify the progression of primary IgA nephropathy. Their core purposes are to reduce proteinuria, mitigate glomerular inflammation and immune-complex injury, preserve glomerular filtration function, and delay kidney failure. Product forms include oral capsules, oral tablets, subcutaneous injections, and intravenous infusion products; their physical appearance may include hard capsules, film-coated tablets, prefilled syringes, ampoules, vials containing sterile liquid, or lyophilized powder. Their composition may include targeted-release corticosteroids, endothelin pathway antagonists, complement pathway inhibitors, antibodies or fusion proteins that suppress pathogenic immunoglobulin production, as well as supportive renal-protective, antiproteinuric, and immunomodulatory medicines. These products must meet pharmaceutical quality management requirements, with strict control over active ingredient purity, impurity profiles, release profiles, sterility assurance, biologic structural consistency, cold-chain stability, and batch-to-batch consistency. The main use scenario is biopsy-confirmed disease with persistent proteinuria or a high risk of renal function decline, while clinical research also covers pediatric patients, post-transplant recurrence, and related glomerular diseases.

The market opportunity for IgA Nephropathy Therapeutics is driven by higher diagnosis rates, stronger nephrology management, and the commercialization of targeted therapies. Historically, treatment relied heavily on supportive care and systemic immunosuppression, both of which had limitations in efficacy and tolerability. Newer

products now target mucosal immunity, endothelin signaling, complement activation, and pathogenic immunoglobulin production, giving high-risk patients more stratified therapeutic options. As proteinuria reduction and renal function preservation become central efficacy measures, products with durable kidney outcome evidence, convenient administration, and combination potential are more likely to gain adoption.

The main market challenges are long-term efficacy validation, reimbursement pressure, and intensifying competition. Some therapies still rely on proteinuria reduction as the basis for accelerated approval, and their ability to prove slower kidney function decline will determine long-term commercial value. The patient population is smaller than that of common chronic diseases, while treatment duration and prices can be high, making payer access and out-of-pocket cost important restraints. Products with different mechanisms may compete, combine, or be used sequentially; safety issues, infection risks, liver monitoring, pregnancy restrictions, administration burden, and rebound after discontinuation may all limit uptake.

Downstream demand is shifting from proteinuria control alone toward full-course kidney function protection. Nephrologists are likely to use risk stratification first, then select therapy according to proteinuria level, renal function slope, blood pressure control, comorbidities, and patient age. High-risk adult patients remain the core commercial population, while pediatric disease, adolescent disease, post-transplant recurrence, and related glomerular disorders may become future expansion areas. Hospitals, specialty pharmacies, commercial insurers, and public reimbursement systems will jointly determine access, while real-world evidence will increasingly shape prescribing behavior and payer negotiations.

LPI (LP Information)'s newest research report, the "IgA Nephropathy Therapeutics Industry Forecast" looks at past sales and reviews total world IgA Nephropathy Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected IgA Nephropathy Therapeutics sales for 2026 through 2032. With IgA Nephropathy Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world IgA Nephropathy Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global IgA Nephropathy Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on IgA Nephropathy Therapeutics portfolios and capabilities, market entry strategies, market

positions, and geographic footprints, to better understand these firms' unique position in an accelerating global IgA Nephropathy Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for IgA Nephropathy Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global IgA Nephropathy Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of IgA Nephropathy Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:

Targeted-release Corticosteroids

Endothelin Pathway Antagonists

Complement Pathway Inhibitors

APRIL/BAFF Pathway Inhibitors

Segmentation by Molecular Nature:

Small-molecule Drugs

Monoclonal Antibodies

Fusion Protein Drugs

Oligonucleotide or RNA Drugs

Segmentation by Dosage Form and Route of Administration:

Oral Drugs

Subcutaneous Injectable Drugs

Intravenous Injectable Drugs

Segmentation by Application:

Clinical Treatment

Drug Experiment

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Novartis

AstraZeneca

Roche

Vertex Pharmaceuticals

Otsuka Pharmaceutical

Asahi Kasei

Traverse Therapeutics

Biogen

Vera Therapeutics

Ionis Pharmaceuticals

STADA Arzneimittel

Ono Pharmaceutical

RemeGen

Everest Medicines

Zai Lab

Regeneron Pharmaceuticals

Boehringer Ingelheim

Eli Lilly

Bayer

Astellas Pharma

Pfizer

Teva Pharmaceutical

Sandoz

Viatis

Sun Pharmaceutical

Dr. Reddy's Laboratories

Aurobindo Pharma

Lupin

Zydus Lifesciences

Cipla

Hikma Pharmaceuticals

Organon

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global IgA Nephropathy Therapeutics Market Size (2021-2032)
 - 2.1.2 IgA Nephropathy Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for IgA Nephropathy Therapeutics by Country/Region (2021, 2025 & 2032)
- 2.2 IgA Nephropathy Therapeutics Segment by Type
 - 2.2.1 Targeted-release Corticosteroids
 - 2.2.2 Endothelin Pathway Antagonists
 - 2.2.3 Complement Pathway Inhibitors
 - 2.2.4 APRIL/BAFF Pathway Inhibitors
 - 2.2.5 IgA Nephropathy Therapeutics Market Size by Type
 - 2.2.5.1 IgA Nephropathy Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.5.2 Global IgA Nephropathy Therapeutics Market Size Market Share by Type (2021-2026)
- 2.3 IgA Nephropathy Therapeutics Segment by Molecular Nature
 - 2.3.1 Small-molecule Drugs
 - 2.3.2 Monoclonal Antibodies
 - 2.3.3 Fusion Protein Drugs
 - 2.3.4 Oligonucleotide or RNA Drugs
 - 2.3.5 IgA Nephropathy Therapeutics Market Size by Molecular Nature
 - 2.3.5.1 IgA Nephropathy Therapeutics Market Size CAGR by Molecular Nature (2021 VS 2025 VS 2032)

2.3.5.2 Global IgA Nephropathy Therapeutics Market Size Market Share by Molecular Nature (2021-2026)

2.4 IgA Nephropathy Therapeutics Segment by Dosage Form and Route of Administration

2.4.1 Oral Drugs

2.4.2 Subcutaneous Injectable Drugs

2.4.3 Intravenous Injectable Drugs

2.4.4 IgA Nephropathy Therapeutics Market Size by Dosage Form and Route of Administration

2.4.4.1 IgA Nephropathy Therapeutics Market Size CAGR by Dosage Form and Route of Administration (2021 VS 2025 VS 2032)

2.4.4.2 Global IgA Nephropathy Therapeutics Market Size Market Share by Dosage Form and Route of Administration (2021-2026)

2.5 IgA Nephropathy Therapeutics Segment by Application

2.5.1 Clinical Treatment

2.5.2 Drug Experiment

2.5.3 IgA Nephropathy Therapeutics Market Size by Application

2.5.3.1 IgA Nephropathy Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)

2.5.3.2 Global IgA Nephropathy Therapeutics Market Size Market Share by Application (2021-2026)

3 IGA NEPHROPATHY THERAPEUTICS MARKET SIZE BY PLAYER

3.1 IgA Nephropathy Therapeutics Market Size Market Share by Player

3.1.1 Global IgA Nephropathy Therapeutics Revenue by Player (2021-2026)

3.1.2 Global IgA Nephropathy Therapeutics Revenue Market Share by Player (2021-2026)

3.2 Global IgA Nephropathy Therapeutics Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 IGA NEPHROPATHY THERAPEUTICS BY REGION

4.1 IgA Nephropathy Therapeutics Market Size by Region (2021-2026)

4.2 Global IgA Nephropathy Therapeutics Annual Revenue by Country/Region (2021-2026)

4.3 Americas IgA Nephropathy Therapeutics Market Size Growth (2021-2026)

4.4 APAC IgA Nephropathy Therapeutics Market Size Growth (2021-2026)

4.5 Europe IgA Nephropathy Therapeutics Market Size Growth (2021-2026)

4.6 Middle East & Africa IgA Nephropathy Therapeutics Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas IgA Nephropathy Therapeutics Market Size by Country (2021-2026)

5.2 Americas IgA Nephropathy Therapeutics Market Size by Type (2021-2026)

5.3 Americas IgA Nephropathy Therapeutics Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC IgA Nephropathy Therapeutics Market Size by Region (2021-2026)

6.2 APAC IgA Nephropathy Therapeutics Market Size by Type (2021-2026)

6.3 APAC IgA Nephropathy Therapeutics Market Size by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe IgA Nephropathy Therapeutics Market Size by Country (2021-2026)

7.2 Europe IgA Nephropathy Therapeutics Market Size by Type (2021-2026)

7.3 Europe IgA Nephropathy Therapeutics Market Size by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa IgA Nephropathy Therapeutics by Region (2021-2026)

8.2 Middle East & Africa IgA Nephropathy Therapeutics Market Size by Type (2021-2026)

8.3 Middle East & Africa IgA Nephropathy Therapeutics Market Size by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL IGA NEPHROPATHY THERAPEUTICS MARKET FORECAST

10.1 Global IgA Nephropathy Therapeutics Forecast by Region (2027-2032)

10.1.1 Global IgA Nephropathy Therapeutics Forecast by Region (2027-2032)

10.1.2 Americas IgA Nephropathy Therapeutics Forecast

10.1.3 APAC IgA Nephropathy Therapeutics Forecast

10.1.4 Europe IgA Nephropathy Therapeutics Forecast

10.1.5 Middle East & Africa IgA Nephropathy Therapeutics Forecast

10.2 Americas IgA Nephropathy Therapeutics Forecast by Country (2027-2032)

10.2.1 United States Market IgA Nephropathy Therapeutics Forecast

10.2.2 Canada Market IgA Nephropathy Therapeutics Forecast

10.2.3 Mexico Market IgA Nephropathy Therapeutics Forecast

10.2.4 Brazil Market IgA Nephropathy Therapeutics Forecast

10.3 APAC IgA Nephropathy Therapeutics Forecast by Region (2027-2032)

10.3.1 China IgA Nephropathy Therapeutics Market Forecast

10.3.2 Japan Market IgA Nephropathy Therapeutics Forecast

10.3.3 Korea Market IgA Nephropathy Therapeutics Forecast

10.3.4 Southeast Asia Market IgA Nephropathy Therapeutics Forecast

- 10.3.5 India Market IgA Nephropathy Therapeutics Forecast
- 10.3.6 Australia Market IgA Nephropathy Therapeutics Forecast
- 10.4 Europe IgA Nephropathy Therapeutics Forecast by Country (2027-2032)
 - 10.4.1 Germany Market IgA Nephropathy Therapeutics Forecast
 - 10.4.2 France Market IgA Nephropathy Therapeutics Forecast
 - 10.4.3 UK Market IgA Nephropathy Therapeutics Forecast
 - 10.4.4 Italy Market IgA Nephropathy Therapeutics Forecast
 - 10.4.5 Russia Market IgA Nephropathy Therapeutics Forecast
- 10.5 Middle East & Africa IgA Nephropathy Therapeutics Forecast by Region (2027-2032)
 - 10.5.1 Egypt Market IgA Nephropathy Therapeutics Forecast
 - 10.5.2 South Africa Market IgA Nephropathy Therapeutics Forecast
 - 10.5.3 Israel Market IgA Nephropathy Therapeutics Forecast
 - 10.5.4 Turkey Market IgA Nephropathy Therapeutics Forecast
- 10.6 Global IgA Nephropathy Therapeutics Forecast by Type (2027-2032)
- 10.7 Global IgA Nephropathy Therapeutics Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market IgA Nephropathy Therapeutics Forecast

11 KEY PLAYERS ANALYSIS

11.1 Novartis

- 11.1.1 Novartis Company Information
- 11.1.2 Novartis IgA Nephropathy Therapeutics Product Offered
- 11.1.3 Novartis IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
- 11.1.4 Novartis Main Business Overview
- 11.1.5 Novartis Latest Developments

11.2 AstraZeneca

- 11.2.1 AstraZeneca Company Information
- 11.2.2 AstraZeneca IgA Nephropathy Therapeutics Product Offered
- 11.2.3 AstraZeneca IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
- 11.2.4 AstraZeneca Main Business Overview
- 11.2.5 AstraZeneca Latest Developments

11.3 Roche

- 11.3.1 Roche Company Information
- 11.3.2 Roche IgA Nephropathy Therapeutics Product Offered
- 11.3.3 Roche IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

- 11.3.4 Roche Main Business Overview
- 11.3.5 Roche Latest Developments
- 11.4 Vertex Pharmaceuticals
 - 11.4.1 Vertex Pharmaceuticals Company Information
 - 11.4.2 Vertex Pharmaceuticals IgA Nephropathy Therapeutics Product Offered
 - 11.4.3 Vertex Pharmaceuticals IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.4.4 Vertex Pharmaceuticals Main Business Overview
 - 11.4.5 Vertex Pharmaceuticals Latest Developments
- 11.5 Otsuka Pharmaceutical
 - 11.5.1 Otsuka Pharmaceutical Company Information
 - 11.5.2 Otsuka Pharmaceutical IgA Nephropathy Therapeutics Product Offered
 - 11.5.3 Otsuka Pharmaceutical IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.5.4 Otsuka Pharmaceutical Main Business Overview
 - 11.5.5 Otsuka Pharmaceutical Latest Developments
- 11.6 Asahi Kasei
 - 11.6.1 Asahi Kasei Company Information
 - 11.6.2 Asahi Kasei IgA Nephropathy Therapeutics Product Offered
 - 11.6.3 Asahi Kasei IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.6.4 Asahi Kasei Main Business Overview
 - 11.6.5 Asahi Kasei Latest Developments
- 11.7 Traveer Therapeutics
 - 11.7.1 Traveer Therapeutics Company Information
 - 11.7.2 Traveer Therapeutics IgA Nephropathy Therapeutics Product Offered
 - 11.7.3 Traveer Therapeutics IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.7.4 Traveer Therapeutics Main Business Overview
 - 11.7.5 Traveer Therapeutics Latest Developments
- 11.8 Biogen
 - 11.8.1 Biogen Company Information
 - 11.8.2 Biogen IgA Nephropathy Therapeutics Product Offered
 - 11.8.3 Biogen IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.8.4 Biogen Main Business Overview
 - 11.8.5 Biogen Latest Developments
- 11.9 Vera Therapeutics
 - 11.9.1 Vera Therapeutics Company Information

- 11.9.2 Vera Therapeutics IgA Nephropathy Therapeutics Product Offered
- 11.9.3 Vera Therapeutics IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
- 11.9.4 Vera Therapeutics Main Business Overview
- 11.9.5 Vera Therapeutics Latest Developments
- 11.10 Ionis Pharmaceuticals
 - 11.10.1 Ionis Pharmaceuticals Company Information
 - 11.10.2 Ionis Pharmaceuticals IgA Nephropathy Therapeutics Product Offered
 - 11.10.3 Ionis Pharmaceuticals IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.10.4 Ionis Pharmaceuticals Main Business Overview
 - 11.10.5 Ionis Pharmaceuticals Latest Developments
- 11.11 STADA Arzneimittel
 - 11.11.1 STADA Arzneimittel Company Information
 - 11.11.2 STADA Arzneimittel IgA Nephropathy Therapeutics Product Offered
 - 11.11.3 STADA Arzneimittel IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.11.4 STADA Arzneimittel Main Business Overview
 - 11.11.5 STADA Arzneimittel Latest Developments
- 11.12 Ono Pharmaceutical
 - 11.12.1 Ono Pharmaceutical Company Information
 - 11.12.2 Ono Pharmaceutical IgA Nephropathy Therapeutics Product Offered
 - 11.12.3 Ono Pharmaceutical IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.12.4 Ono Pharmaceutical Main Business Overview
 - 11.12.5 Ono Pharmaceutical Latest Developments
- 11.13 RemeGen
 - 11.13.1 RemeGen Company Information
 - 11.13.2 RemeGen IgA Nephropathy Therapeutics Product Offered
 - 11.13.3 RemeGen IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.13.4 RemeGen Main Business Overview
 - 11.13.5 RemeGen Latest Developments
- 11.14 Everest Medicines
 - 11.14.1 Everest Medicines Company Information
 - 11.14.2 Everest Medicines IgA Nephropathy Therapeutics Product Offered
 - 11.14.3 Everest Medicines IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.14.4 Everest Medicines Main Business Overview

- 11.14.5 Everest Medicines Latest Developments
- 11.15 Zai Lab
 - 11.15.1 Zai Lab Company Information
 - 11.15.2 Zai Lab IgA Nephropathy Therapeutics Product Offered
 - 11.15.3 Zai Lab IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.15.4 Zai Lab Main Business Overview
 - 11.15.5 Zai Lab Latest Developments
- 11.16 Regeneron Pharmaceuticals
 - 11.16.1 Regeneron Pharmaceuticals Company Information
 - 11.16.2 Regeneron Pharmaceuticals IgA Nephropathy Therapeutics Product Offered
 - 11.16.3 Regeneron Pharmaceuticals IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.16.4 Regeneron Pharmaceuticals Main Business Overview
 - 11.16.5 Regeneron Pharmaceuticals Latest Developments
- 11.17 Boehringer Ingelheim
 - 11.17.1 Boehringer Ingelheim Company Information
 - 11.17.2 Boehringer Ingelheim IgA Nephropathy Therapeutics Product Offered
 - 11.17.3 Boehringer Ingelheim IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.17.4 Boehringer Ingelheim Main Business Overview
 - 11.17.5 Boehringer Ingelheim Latest Developments
- 11.18 Eli Lilly
 - 11.18.1 Eli Lilly Company Information
 - 11.18.2 Eli Lilly IgA Nephropathy Therapeutics Product Offered
 - 11.18.3 Eli Lilly IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.18.4 Eli Lilly Main Business Overview
 - 11.18.5 Eli Lilly Latest Developments
- 11.19 Bayer
 - 11.19.1 Bayer Company Information
 - 11.19.2 Bayer IgA Nephropathy Therapeutics Product Offered
 - 11.19.3 Bayer IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.19.4 Bayer Main Business Overview
 - 11.19.5 Bayer Latest Developments
- 11.20 Astellas Pharma
 - 11.20.1 Astellas Pharma Company Information
 - 11.20.2 Astellas Pharma IgA Nephropathy Therapeutics Product Offered

11.20.3 Astellas Pharma IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.20.4 Astellas Pharma Main Business Overview

11.20.5 Astellas Pharma Latest Developments

11.21 Pfizer

11.21.1 Pfizer Company Information

11.21.2 Pfizer IgA Nephropathy Therapeutics Product Offered

11.21.3 Pfizer IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.21.4 Pfizer Main Business Overview

11.21.5 Pfizer Latest Developments

11.22 Teva Pharmaceutical

11.22.1 Teva Pharmaceutical Company Information

11.22.2 Teva Pharmaceutical IgA Nephropathy Therapeutics Product Offered

11.22.3 Teva Pharmaceutical IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.22.4 Teva Pharmaceutical Main Business Overview

11.22.5 Teva Pharmaceutical Latest Developments

11.23 Sandoz

11.23.1 Sandoz Company Information

11.23.2 Sandoz IgA Nephropathy Therapeutics Product Offered

11.23.3 Sandoz IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.23.4 Sandoz Main Business Overview

11.23.5 Sandoz Latest Developments

11.24 Viatris

11.24.1 Viatris Company Information

11.24.2 Viatris IgA Nephropathy Therapeutics Product Offered

11.24.3 Viatris IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.24.4 Viatris Main Business Overview

11.24.5 Viatris Latest Developments

11.25 Sun Pharmaceutical

11.25.1 Sun Pharmaceutical Company Information

11.25.2 Sun Pharmaceutical IgA Nephropathy Therapeutics Product Offered

11.25.3 Sun Pharmaceutical IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.25.4 Sun Pharmaceutical Main Business Overview

11.25.5 Sun Pharmaceutical Latest Developments

11.26 Dr. Reddy's Laboratories

11.26.1 Dr. Reddy's Laboratories Company Information

11.26.2 Dr. Reddy's Laboratories IgA Nephropathy Therapeutics Product Offered

11.26.3 Dr. Reddy's Laboratories IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.26.4 Dr. Reddy's Laboratories Main Business Overview

11.26.5 Dr. Reddy's Laboratories Latest Developments

11.27 Aurobindo Pharma

11.27.1 Aurobindo Pharma Company Information

11.27.2 Aurobindo Pharma IgA Nephropathy Therapeutics Product Offered

11.27.3 Aurobindo Pharma IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.27.4 Aurobindo Pharma Main Business Overview

11.27.5 Aurobindo Pharma Latest Developments

11.28 Lupin

11.28.1 Lupin Company Information

11.28.2 Lupin IgA Nephropathy Therapeutics Product Offered

11.28.3 Lupin IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.28.4 Lupin Main Business Overview

11.28.5 Lupin Latest Developments

11.29 Zydus Lifesciences

11.29.1 Zydus Lifesciences Company Information

11.29.2 Zydus Lifesciences IgA Nephropathy Therapeutics Product Offered

11.29.3 Zydus Lifesciences IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.29.4 Zydus Lifesciences Main Business Overview

11.29.5 Zydus Lifesciences Latest Developments

11.30 Cipla

11.30.1 Cipla Company Information

11.30.2 Cipla IgA Nephropathy Therapeutics Product Offered

11.30.3 Cipla IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.30.4 Cipla Main Business Overview

11.30.5 Cipla Latest Developments

11.31 Hikma Pharmaceuticals

11.31.1 Hikma Pharmaceuticals Company Information

11.31.2 Hikma Pharmaceuticals IgA Nephropathy Therapeutics Product Offered

11.31.3 Hikma Pharmaceuticals IgA Nephropathy Therapeutics Revenue, Gross

Margin and Market Share (2021-2026)

11.31.4 Hikma Pharmaceuticals Main Business Overview

11.31.5 Hikma Pharmaceuticals Latest Developments

11.32 Organon

11.32.1 Organon Company Information

11.32.2 Organon IgA Nephropathy Therapeutics Product Offered

11.32.3 Organon IgA Nephropathy Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.32.4 Organon Main Business Overview

11.32.5 Organon Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. IgA Nephropathy Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. IgA Nephropathy Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Targeted-release Corticosteroids

Table 4. Major Players of Endothelin Pathway Antagonists

Table 5. Major Players of Complement Pathway Inhibitors

Table 6. Major Players of APRIL/BAFF Pathway Inhibitors

Table 7. IgA Nephropathy Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 8. Global IgA Nephropathy Therapeutics Market Size by Type (2021-2026) & (\$ millions)

Table 9. Global IgA Nephropathy Therapeutics Market Size Market Share by Type (2021-2026)

Table 10. Major Players of Small-molecule Drugs

Table 11. Major Players of Monoclonal Antibodies

Table 12. Major Players of Fusion Protein Drugs

Table 13. Major Players of Oligonucleotide or RNA Drugs

Table 14. IgA Nephropathy Therapeutics Market Size CAGR by Molecular Nature (2021 VS 2025 VS 2032) & (\$ millions)

Table 15. Global IgA Nephropathy Therapeutics Market Size by Molecular Nature (2021-2026) & (\$ millions)

Table 16. Global IgA Nephropathy Therapeutics Market Size Market Share by Molecular Nature (2021-2026)

Table 17. Major Players of Oral Drugs

Table 18. Major Players of Subcutaneous Injectable Drugs

Table 19. Major Players of Intravenous Injectable Drugs

Table 20. IgA Nephropathy Therapeutics Market Size CAGR by Dosage Form and Route of Administration (2021 VS 2025 VS 2032) & (\$ millions)

Table 21. Global IgA Nephropathy Therapeutics Market Size by Dosage Form and Route of Administration (2021-2026) & (\$ millions)

Table 22. Global IgA Nephropathy Therapeutics Market Size Market Share by Dosage Form and Route of Administration (2021-2026)

Table 23. IgA Nephropathy Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 24. Global IgA Nephropathy Therapeutics Market Size by Application (2021-2026) & (\$ millions)

Table 25. Global IgA Nephropathy Therapeutics Market Size Market Share by Application (2021-2026)

Table 26. Global IgA Nephropathy Therapeutics Revenue by Player (2021-2026) & (\$ millions)

Table 27. Global IgA Nephropathy Therapeutics Revenue Market Share by Player (2021-2026)

Table 28. IgA Nephropathy Therapeutics Key Players Head office and Products Offered

Table 29. IgA Nephropathy Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 30. New Products and Potential Entrants

Table 31. Mergers & Acquisitions, Expansion

Table 32. Global IgA Nephropathy Therapeutics Market Size by Region (2021-2026) & (\$ millions)

Table 33. Global IgA Nephropathy Therapeutics Market Size Market Share by Region (2021-2026)

Table 34. Global IgA Nephropathy Therapeutics Revenue by Country/Region (2021-2026) & (\$ millions)

Table 35. Global IgA Nephropathy Therapeutics Revenue Market Share by Country/Region (2021-2026)

Table 36. Americas IgA Nephropathy Therapeutics Market Size by Country (2021-2026) & (\$ millions)

Table 37. Americas IgA Nephropathy Therapeutics Market Size Market Share by Country (2021-2026)

Table 38. Americas IgA Nephropathy Therapeutics Market Size by Type (2021-2026) & (\$ millions)

Table 39. Americas IgA Nephropathy Therapeutics Market Size Market Share by Type (2021-2026)

Table 40. Americas IgA Nephropathy Therapeutics Market Size by Application (2021-2026) & (\$ millions)

Table 41. Americas IgA Nephropathy Therapeutics Market Size Market Share by Application (2021-2026)

Table 42. APAC IgA Nephropathy Therapeutics Market Size by Region (2021-2026) & (\$ millions)

Table 43. APAC IgA Nephropathy Therapeutics Market Size Market Share by Region (2021-2026)

Table 44. APAC IgA Nephropathy Therapeutics Market Size by Type (2021-2026) & (\$ millions)

Table 45. APAC IgA Nephropathy Therapeutics Market Size by Application (2021-2026) & (\$ millions)

Table 46. Europe IgA Nephropathy Therapeutics Market Size by Country (2021-2026) & (\$ millions)

Table 47. Europe IgA Nephropathy Therapeutics Market Size Market Share by Country (2021-2026)

Table 48. Europe IgA Nephropathy Therapeutics Market Size by Type (2021-2026) & (\$ millions)

Table 49. Europe IgA Nephropathy Therapeutics Market Size by Application (2021-2026) & (\$ millions)

Table 50. Middle East & Africa IgA Nephropathy Therapeutics Market Size by Region (2021-2026) & (\$ millions)

Table 51. Middle East & Africa IgA Nephropathy Therapeutics Market Size by Type (2021-2026) & (\$ millions)

Table 52. Middle East & Africa IgA Nephropathy Therapeutics Market Size by Application (2021-2026) & (\$ millions)

Table 53. Key Market Drivers & Growth Opportunities of IgA Nephropathy Therapeutics

Table 54. Key Market Challenges & Risks of IgA Nephropathy Therapeutics

Table 55. Key Industry Trends of IgA Nephropathy Therapeutics

Table 56. Global IgA Nephropathy Therapeutics Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 57. Global IgA Nephropathy Therapeutics Market Size Market Share Forecast by Region (2027-2032)

Table 58. Global IgA Nephropathy Therapeutics Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 59. Global IgA Nephropathy Therapeutics Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 60. Novartis Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 61. Novartis IgA Nephropathy Therapeutics Product Offered

Table 62. Novartis IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 63. Novartis Main Business

Table 64. Novartis Latest Developments

Table 65. AstraZeneca Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 66. AstraZeneca IgA Nephropathy Therapeutics Product Offered

Table 67. AstraZeneca IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 68. AstraZeneca Main Business

Table 69. AstraZeneca Latest Developments

Table 70. Roche Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 71. Roche IgA Nephropathy Therapeutics Product Offered

Table 72. Roche IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 73. Roche Main Business

Table 74. Roche Latest Developments

Table 75. Vertex Pharmaceuticals Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 76. Vertex Pharmaceuticals IgA Nephropathy Therapeutics Product Offered

Table 77. Vertex Pharmaceuticals IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 78. Vertex Pharmaceuticals Main Business

Table 79. Vertex Pharmaceuticals Latest Developments

Table 80. Otsuka Pharmaceutical Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 81. Otsuka Pharmaceutical IgA Nephropathy Therapeutics Product Offered

Table 82. Otsuka Pharmaceutical IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 83. Otsuka Pharmaceutical Main Business

Table 84. Otsuka Pharmaceutical Latest Developments

Table 85. Asahi Kasei Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 86. Asahi Kasei IgA Nephropathy Therapeutics Product Offered

Table 87. Asahi Kasei IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 88. Asahi Kasei Main Business

Table 89. Asahi Kasei Latest Developments

Table 90. Travele Therapeutics Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 91. Travele Therapeutics IgA Nephropathy Therapeutics Product Offered

Table 92. Travele Therapeutics IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 93. Travele Therapeutics Main Business

Table 94. Travele Therapeutics Latest Developments

Table 95. Biogen Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 96. Biogen IgA Nephropathy Therapeutics Product Offered
Table 97. Biogen IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 98. Biogen Main Business
Table 99. Biogen Latest Developments
Table 100. Vera Therapeutics Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 101. Vera Therapeutics IgA Nephropathy Therapeutics Product Offered
Table 102. Vera Therapeutics IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 103. Vera Therapeutics Main Business
Table 104. Vera Therapeutics Latest Developments
Table 105. Ionis Pharmaceuticals Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 106. Ionis Pharmaceuticals IgA Nephropathy Therapeutics Product Offered
Table 107. Ionis Pharmaceuticals IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 108. Ionis Pharmaceuticals Main Business
Table 109. Ionis Pharmaceuticals Latest Developments
Table 110. STADA Arzneimittel Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 111. STADA Arzneimittel IgA Nephropathy Therapeutics Product Offered
Table 112. STADA Arzneimittel IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 113. STADA Arzneimittel Main Business
Table 114. STADA Arzneimittel Latest Developments
Table 115. Ono Pharmaceutical Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 116. Ono Pharmaceutical IgA Nephropathy Therapeutics Product Offered
Table 117. Ono Pharmaceutical IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 118. Ono Pharmaceutical Main Business
Table 119. Ono Pharmaceutical Latest Developments
Table 120. RemeGen Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 121. RemeGen IgA Nephropathy Therapeutics Product Offered
Table 122. RemeGen IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 123. RemeGen Main Business

Table 124. RemeGen Latest Developments
Table 125. Everest Medicines Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 126. Everest Medicines IgA Nephropathy Therapeutics Product Offered
Table 127. Everest Medicines IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 128. Everest Medicines Main Business
Table 129. Everest Medicines Latest Developments
Table 130. Zai Lab Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 131. Zai Lab IgA Nephropathy Therapeutics Product Offered
Table 132. Zai Lab IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 133. Zai Lab Main Business
Table 134. Zai Lab Latest Developments
Table 135. Regeneron Pharmaceuticals Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 136. Regeneron Pharmaceuticals IgA Nephropathy Therapeutics Product Offered
Table 137. Regeneron Pharmaceuticals IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 138. Regeneron Pharmaceuticals Main Business
Table 139. Regeneron Pharmaceuticals Latest Developments
Table 140. Boehringer Ingelheim Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 141. Boehringer Ingelheim IgA Nephropathy Therapeutics Product Offered
Table 142. Boehringer Ingelheim IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 143. Boehringer Ingelheim Main Business
Table 144. Boehringer Ingelheim Latest Developments
Table 145. Eli Lilly Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 146. Eli Lilly IgA Nephropathy Therapeutics Product Offered
Table 147. Eli Lilly IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 148. Eli Lilly Main Business
Table 149. Eli Lilly Latest Developments
Table 150. Bayer Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors
Table 151. Bayer IgA Nephropathy Therapeutics Product Offered

Table 152. Bayer IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 153. Bayer Main Business

Table 154. Bayer Latest Developments

Table 155. Astellas Pharma Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 156. Astellas Pharma IgA Nephropathy Therapeutics Product Offered

Table 157. Astellas Pharma IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 158. Astellas Pharma Main Business

Table 159. Astellas Pharma Latest Developments

Table 160. Pfizer Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 161. Pfizer IgA Nephropathy Therapeutics Product Offered

Table 162. Pfizer IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 163. Pfizer Main Business

Table 164. Pfizer Latest Developments

Table 165. Teva Pharmaceutical Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 166. Teva Pharmaceutical IgA Nephropathy Therapeutics Product Offered

Table 167. Teva Pharmaceutical IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 168. Teva Pharmaceutical Main Business

Table 169. Teva Pharmaceutical Latest Developments

Table 170. Sandoz Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 171. Sandoz IgA Nephropathy Therapeutics Product Offered

Table 172. Sandoz IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 173. Sandoz Main Business

Table 174. Sandoz Latest Developments

Table 175. Viartis Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 176. Viartis IgA Nephropathy Therapeutics Product Offered

Table 177. Viartis IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 178. Viartis Main Business

Table 179. Viartis Latest Developments

Table 180. Sun Pharmaceutical Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 181. Sun Pharmaceutical IgA Nephropathy Therapeutics Product Offered

Table 182. Sun Pharmaceutical IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 183. Sun Pharmaceutical Main Business

Table 184. Sun Pharmaceutical Latest Developments

Table 185. Dr. Reddy's Laboratories Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 186. Dr. Reddy's Laboratories IgA Nephropathy Therapeutics Product Offered

Table 187. Dr. Reddy's Laboratories IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 188. Dr. Reddy's Laboratories Main Business

Table 189. Dr. Reddy's Laboratories Latest Developments

Table 190. Aurobindo Pharma Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 191. Aurobindo Pharma IgA Nephropathy Therapeutics Product Offered

Table 192. Aurobindo Pharma IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 193. Aurobindo Pharma Main Business

Table 194. Aurobindo Pharma Latest Developments

Table 195. Lupin Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 196. Lupin IgA Nephropathy Therapeutics Product Offered

Table 197. Lupin IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 198. Lupin Main Business

Table 199. Lupin Latest Developments

Table 200. Zydus Lifesciences Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 201. Zydus Lifesciences IgA Nephropathy Therapeutics Product Offered

Table 202. Zydus Lifesciences IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 203. Zydus Lifesciences Main Business

Table 204. Zydus Lifesciences Latest Developments

Table 205. Cipla Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 206. Cipla IgA Nephropathy Therapeutics Product Offered

Table 207. Cipla IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and

Market Share (2021-2026)

Table 208. Cipla Main Business

Table 209. Cipla Latest Developments

Table 210. Hikma Pharmaceuticals Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 211. Hikma Pharmaceuticals IgA Nephropathy Therapeutics Product Offered

Table 212. Hikma Pharmaceuticals IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 213. Hikma Pharmaceuticals Main Business

Table 214. Hikma Pharmaceuticals Latest Developments

Table 215. Organon Details, Company Type, IgA Nephropathy Therapeutics Area Served and Its Competitors

Table 216. Organon IgA Nephropathy Therapeutics Product Offered

Table 217. Organon IgA Nephropathy Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 218. Organon Main Business

Table 219. Organon Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. IgA Nephropathy Therapeutics Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global IgA Nephropathy Therapeutics Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. IgA Nephropathy Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. IgA Nephropathy Therapeutics Sales Market Share by Country/Region (2025)

Figure 8. IgA Nephropathy Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global IgA Nephropathy Therapeutics Market Size Market Share by Type in 2025

Figure 10. Global IgA Nephropathy Therapeutics Market Size Market Share by Molecular Nature in 2025

Figure 11. Global IgA Nephropathy Therapeutics Market Size Market Share by Dosage Form and Route of Administration in 2025

Figure 12. IgA Nephropathy Therapeutics in Clinical Treatment

Figure 13. Global IgA Nephropathy Therapeutics Market: Clinical Treatment (2021-2026) & (\$ millions)

Figure 14. IgA Nephropathy Therapeutics in Drug Experiment

Figure 15. Global IgA Nephropathy Therapeutics Market: Drug Experiment (2021-2026) & (\$ millions)

Figure 16. Global IgA Nephropathy Therapeutics Market Size Market Share by Application in 2025

Figure 17. Global IgA Nephropathy Therapeutics Revenue Market Share by Player in 2025

Figure 18. Global IgA Nephropathy Therapeutics Market Size Market Share by Region (2021-2026)

Figure 19. Americas IgA Nephropathy Therapeutics Market Size 2021-2026 (\$ millions)

Figure 20. APAC IgA Nephropathy Therapeutics Market Size 2021-2026 (\$ millions)

Figure 21. Europe IgA Nephropathy Therapeutics Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa IgA Nephropathy Therapeutics Market Size 2021-2026 (\$ millions)

Figure 23. Americas IgA Nephropathy Therapeutics Value Market Share by Country in

2025

Figure 24. United States IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC IgA Nephropathy Therapeutics Market Size Market Share by Region in 2025

Figure 29. APAC IgA Nephropathy Therapeutics Market Size Market Share by Type (2021-2026)

Figure 30. APAC IgA Nephropathy Therapeutics Market Size Market Share by Application (2021-2026)

Figure 31. China IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 35. India IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe IgA Nephropathy Therapeutics Market Size Market Share by Country in 2025

Figure 38. Europe IgA Nephropathy Therapeutics Market Size Market Share by Type (2021-2026)

Figure 39. Europe IgA Nephropathy Therapeutics Market Size Market Share by Application (2021-2026)

Figure 40. Germany IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 41. France IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 42. UK IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 43. Italy IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 44. Russia IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 45. Middle East & Africa IgA Nephropathy Therapeutics Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa IgA Nephropathy Therapeutics Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa IgA Nephropathy Therapeutics Market Size Market Share by Application (2021-2026)

Figure 48. Egypt IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries IgA Nephropathy Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 54. APAC IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 55. Europe IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 57. United States IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 58. Canada IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 59. Mexico IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 60. Brazil IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 61. China IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 62. Japan IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 63. Korea IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 65. India IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 66. Australia IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 67. Germany IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 68. France IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 69. UK IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 70. Italy IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 71. Russia IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 72. Egypt IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 73. South Africa IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 74. Israel IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 75. Turkey IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

Figure 76. Global IgA Nephropathy Therapeutics Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global IgA Nephropathy Therapeutics Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries IgA Nephropathy Therapeutics Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global IgA Nephropathy Therapeutics Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G1A8F26503BEEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1A8F26503BEEN.html>